Search Results for "Aziza Othmana W Kip Dia"

12:27 EDT 23rd May 2015 | BioPortfolio

Matching Channels


Matching News

Genclis SAS Coordinate a Roundtable in a Molecular Allergology Seminar

Nancy, France, November 20, 2014 - Genclis, a molecular diagnostic company in the fields of allergy and cancer, will attend the 2nd French Molecular Allergology Seminar in Paris on November 22 ...

INNATE PHARMA announces its 2015 FINANCIAL CALENDAR as well as its participation in upcoming investor conferences

Marseille, France, December 02, 2014 Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic ant...

VECT-HORUS: new equity issue of 1.5 M€ to finance the preclinical development of its first vectorized product

Vect-Horus, a biotechnology company that designs and develops peptide vectors that facilitate the delivery of drugs or imaging agents, notably in the brain, announced today having raised € 1.5...

Genclis selected to present its diagnostic technology Severidia® at the St. Gallen International Breast Cancer Conference

Presentation on using next generation sequencing to predict triple-negative breast cancer outcome Nancy, France, January 9, 2015 - Genclis, a molecular diagnostic company in the fields of al...

BIOASTER is increasing its bioinformatic capabilities by signing a strategic partnership with IN2P3 Computing Center (CNRS)

Mass data storage and subatomic physics and astrophysics computing power are now being made available to the field of health-related and infectious disease microbiology. Lyon and Villeu...

Genclis SAS : Confirms Potential of its Severidia® Test on 47 TNBC patients

 100% of patients classified with Severidia® in the "good outcome" subgroup were alive after 2,500 days Improved p value (p < 10-5) Nancy, France, November 25, 2014 -...

Nick Jonas and Duracell Power Smiles for Children’s Miracle Network This Holiday Season

Jonas encourages Canadians to get involved as Duracell looks to donate $150,000 to Children’s Miracle Network and batteries to hospital playrooms Multi-talented recor...

INNATE PHARMA: First Phase II trial with IPH2201 open in head and neck cancer

First Phase II of IPH2201, a novel checkpoint inhibitor entering the immuno-oncology field Marseille, France, December 19, 2014 Innate Pharma SA (the "Company" - Euronext Pa...

Matching PubMed Articles


Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement